Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study

被引：0

作者：

Ashina, Messoud ^{[1
,2
,3
]}

Tepper, Stewart J. ^{[4
]}

Brandes, Jan Lewis ^{[5
,6
]}

Reuter, Uwe ^{[7
]}

Boudreau, Guy P. ^{[8
]}

Dolezil, David ^{[9
]}

Cheng, Sunfa ^{[10
]}

Leonardi, Dean ^{[10
]}

Lenz, Robert A. ^{[10
]}

Klatt, Jan ^{[11
]}

Mikol, Daniel D. ^{[10
]}

机构：

[1] Rigshosp, Danish Headache Ctr, Glostrup, Denmark

[2] Rigshosp, Dept Neurol, Glostrup, Denmark

[3] Univ Copenhagen, Fac Med & Hlth Sci, Copenhagen, Denmark

[4] Geisel Sch Med Dartmouth, Hanover, NH USA

[5] Nashville Neurosci Grp, Nashville, TN USA

[6] Vanderbilt Univ, Sch Neurol, Nashville, TN 37235 USA

[7] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[8] Univ Hosp Ctr Montreal, Neurol Dept, Headache Unit, Montreal, PQ, Canada

[9] DADO Med Sro, Prague Headache Ctr, Prague, Czech Republic

[10] Amgen Inc, Thousand Oaks, CA 91320 USA

[11] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF HEADACHE AND PAIN | 2017年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页数：1

共 50 条

[1] Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study
Ashina, M.
Tepper, S.
Brandes, J.
Reuter, U.
Boudreau, G.
Dolezil, D.
Cheng, S.
Leonardi, D.
Lenz, R.
Mikol, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 470 - 471
[2] Efficacy of erenumab (AMG 334) in patients with chronic migraine in North America and Europe: Subgroup analysis of a phase 2, randomised, double-blind, placebo-controlled study
Reuter, U.
Brandes, J.
Dolezil, D.
Tepper, S.
Cheng, S.
Leonardi, D.
Lenz, R.
Mikol, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 548 - 548
[3] Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Ashina, Messoud
Tepper, Stewart
Brandes, Jan Lewis
Reuter, Uwe
Boudreau, Guy
Dolezil, David
Cheng, Sunfa
Zhang, Feng
Lenz, Robert
Klatt, Jan
Mikol, Daniel D.
CEPHALALGIA, 2018, 38 (10) : 1611 - 1621
[4] Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Goadsby, Peter J.
Paemeleire, Koen
Broessner, Gregor
Brandes, Jan
Klatt, Jan
Zhang, Feng
Picard, Hernan
Lenz, Robert
Mikol, Daniel D.
CEPHALALGIA, 2019, 39 (07) : 817 - 826
[5] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
Tepper, S. J.
Dolezil, D.
Ashina, M.
Reuter, U.
Brandes, J. L.
Silberstein, S. D.
Winner, P.
Leonardi, D. K.
Mikol, D. D.
HEADACHE, 2017, 57 : 130 - 130
[6] Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Tepper, Stewart
Widnell, Katherine
Dolezil, David
Ashina, Messoud
Reuter, Uwe
Brandes, Jan Lewis
Silberstein, Stephen
Winner, Paul
Leonardi, Dean
Mikol, Dan
NEUROLOGY, 2017, 88
[7] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
Tepper, S.
Widnell, K.
Dolezil, D.
Ashina, M.
Reuter, U.
Brandes, J. Lewis
Silberstein, S.
Winner, P.
Leonardi, D.
Mikol, D.
CEPHALALGIA, 2016, 36 : 44 - 45
[8] Efficacy of Erenumab (a fully human Mab targeting the CGRP receptor) in Chronic Migraine Patients with Prior Treatment Failure: a Subgroup Analysis of the Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Ashina, Messoud
Tepper, Stewart
Brandes, Jan L.
Reuter, Uwe
Boudreau, Guy
Dolezil, David
Cheng, Sunfa
Leonardi, Dean
Lenz, Robert
Klatt, Jan
Mikol, Daniel
CEPHALALGIA, 2017, 37 : 326 - 328
[9] Patient-reported outcomes in patients with chronic migraine receiving placebo or erenumab (AMG 334) in a phase 2, randomised, double-blind study
Lipton, Richard B.
Tepper, Stewart J.
Reuter, Uwe
Silberstein, Stephen
Stewart, Walter
Leonardi, Dean
Desai, Pooja
Cheng, Sunfa
Mikol, Daniel D.
Lenz, Robert A.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[10] Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Sun, Hong
Dodick, David W.
Silberstein, Stephen
Goadsby, Peter J.
Reuter, Uwe
Ashina, Messoud
Saper, Joel
Cady, Roger
Chon, Yun
Dietrich, Julie
Lenz, Robert
LANCET NEUROLOGY, 2016, 15 (04): : 382 - 390

← 1 2 3 4 5 →